ID
24570
Description
Study ID: 100470 Clinical Study ID: SCO100470 Study Title: A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone propionate/salmeterol Trade Name: Serevent Study Indication: Pulmonary Disease, Chronic Obstructive
Keywords
Versions (1)
- 8/6/17 8/6/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 6, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
COPD excerbation salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470
COPD excerbation salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470
Description
If "yes" to COPD exacerbation, record following items.
Alias
- UMLS CUI-1
- C0740304
Description
date of onset of COPD exacerbation
Data type
date
Alias
- UMLS CUI [1,1]
- C0574845
- UMLS CUI [1,2]
- C0740304
Description
outcome of COPD exacerbation
Data type
integer
Alias
- UMLS CUI [1,1]
- C0085565
- UMLS CUI [1,2]
- C0740304
Description
date of resolution or death
Data type
date
Alias
- UMLS CUI [1]
- C2985858
- UMLS CUI [2]
- C1148348
Description
severity of COPD excerbation
Data type
integer
Alias
- UMLS CUI [1,1]
- C0439793
- UMLS CUI [1,2]
- C0740304
Description
Subjects who experience more than one moderate exacerbation requiring antibiotic and/or oral corticosteroid treatment during the treatment period and/or experience a severe exacerbation requiring hospitalisation during the course of the study must be withdrawn.
Data type
text
Alias
- UMLS CUI [1,1]
- C0422727
- UMLS CUI [1,2]
- C0740304
Similar models
COPD excerbation salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470
C0740304 (UMLS CUI [1,2])
C0740304 (UMLS CUI [1,2])
C1148348 (UMLS CUI [2])
C0740304 (UMLS CUI [1,2])
C0740304 (UMLS CUI [1,2])